Quality of life and adjuvant systemic therapy for early-stage breast cancer (Q37008863)

17 August 2017

1 reference

title

Quality of life and adjuvant systemic therapy for early-stage breast cancer (English)

1 reference

17 August 2017

1 reference

1 reference

1 reference

Peter S Grimison

1

1 reference

PubMed ID

18028021

17 August 2017

Martin R Stockler

series ordinal

2

1 reference

17 August 2017

1 August 2007

1 reference

Expert Review of Anticancer Therapy

17 August 2017

1 reference

17 August 2017

7

1 reference

17 August 2017

8

1 reference

17 August 2017

1123-1134

1 reference

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

17 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

First--select the target: better choice of adjuvant treatments for breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Measuring quality of life in chronic illness: the functional assessment of chronic illness therapy measurement system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Quality of life: a new perspective for cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Evolution of breast cancer treatments: current options and quality-of-life considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for 'well-tolerated' treatments?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Breast cancer patients on adjuvant chemotherapy report a wide range of problems not identified by health-care staff.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

The impact of endocrine therapy on patients with breast cancer: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. The International Breast Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

The European Organization for Research and Treatment of Cancer. Approach to quality of life assessment: guidelines for developing questionnaire modules. EORTC Study Group on Quality of Life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Practical approaches to minimize problems with missing quality of life data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Missing quality of life data in cancer clinical trials: serious problems and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

High dose chemotherapy for poor prognosis breast cancer: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Quality of life measures for patients receiving adjuvant therapy for breast cancer: an international trial. The International Breast Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Adjuvant docetaxel for node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Grou

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: a prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Randomized trial of adjuvant tamoxifen and/or goserelin in premenopausal breast cancer--self-rated physiological effects and symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Side Effects of Adjuvant Endocrine Treatment in Premenopausal Breast Cancer Patients: A Prospective Randomized Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Breast Cancer in Younger Women: Reproductive and Late Health Effects of Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

The effects of adjuvant chemotherapy on cognition in women with breast cancer--preliminary results of an observational longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Quality of life among long-term breast cancer survivors: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Quality of life among younger women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

The psychosocial needs of breast cancer survivors; a qualitative study of the shared and unique needs of younger versus older survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Cancer survivorship: a new challenge in delivering quality cancer care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Patient online self-reporting of toxicity symptoms during chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Patients' preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Same gain, less pain: potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Physician/patient decision aids for adjuvant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Modelling valuations for Eq-5d health states: an alternative model using differences in valuations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Simultaneous analysis of quality of life and survival data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Combining symptom and survival data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Q-TWiST analysis of cyclophosphamide, epirubicin, fluorouracil versus cyclophosphamide, methotrexate, fluorouracil treatment for premenopausal women with node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

The MOS 36-ltem Short-Form Health Survey (SF-36)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

The hospital anxiety and depression scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

The Sexual Activity Questionnaire: a measure of women's sexual functioning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1123

10.1586/14737140.7.8.1123

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

18028021